Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 94 entries
Sorted by: Best Match Show Resources per page
Immunotherapy with a sting.

Science (New York, N.Y.)

Gajewski TF, Higgs EF.
PMID: 32820113
Science. 2020 Aug 21;369(6506):921-922. doi: 10.1126/science.abc6622.

No abstract available.

Cite
Gajewski TF, Higgs EF. Immunotherapy with a sting. Science. 2020;369(6506):921-922doi: 10.1126/science.abc6622.
Gajewski, T. F., & Higgs, E. F. (2020). Immunotherapy with a sting. Science (New York, N.Y.), 369(6506), 921-922. https://doi.org/10.1126/science.abc6622
Gajewski, Thomas F, and Higgs, Emily F. "Immunotherapy with a sting." Science (New York, N.Y.) vol. 369,6506 (2020): 921-922. doi: https://doi.org/10.1126/science.abc6622
Gajewski TF, Higgs EF. Immunotherapy with a sting. Science. 2020 Aug 21;369(6506):921-922. doi: 10.1126/science.abc6622. PMID: 32820113.
Copy Download .nbib Format: NLM
The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.

Future medicinal chemistry

Qiu J, Sharma S, Rollins RA, Paul TA.
PMID: 32723083
Future Med Chem. 2020 Aug;12(15):1415-1430. doi: 10.4155/fmc-2020-0072. Epub 2020 Jul 29.

Immune dysfunction in the tumor microenvironment occurs through epigenetic changes in both tumor cells and immune cells that alter transcriptional programs driving cell fate and cell function. Oncogenic activation of the histone methyltransferase EZH2 mediates gene expression changes, governing...

Cite
Qiu J, Sharma S, Rollins RA, et al. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future Med Chem. 2020;12(15):1415-1430doi: 10.4155/fmc-2020-0072.
Qiu, J., Sharma, S., Rollins, R. A., & Paul, T. A. (2020). The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future medicinal chemistry, 12(15), 1415-1430. https://doi.org/10.4155/fmc-2020-0072
Qiu, Jing, et al. "The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations." Future medicinal chemistry vol. 12,15 (2020): 1415-1430. doi: https://doi.org/10.4155/fmc-2020-0072
Qiu J, Sharma S, Rollins RA, Paul TA. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations. Future Med Chem. 2020 Aug;12(15):1415-1430. doi: 10.4155/fmc-2020-0072. Epub 2020 Jul 29. PMID: 32723083.
Copy Download .nbib Format: NLM
Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation.

Cancer immunology, immunotherapy : CII

Couchoud C, Fagnoni P, Aubin F, Westeel V, Maurina T, Thiery-Vuillemin A, Gerard C, Kroemer M, Borg C, Limat S, Nerich V.
PMID: 32676716
Cancer Immunol Immunother. 2020 Oct;69(10):1947-1958. doi: 10.1007/s00262-020-02646-0. Epub 2020 Jul 16.

OBJECTIVES: Scientific advances in the last decade have highlighted the use of immunotherapy, especially immune checkpoint inhibitors, to be an effective strategy in cancer therapy. However, these immunotherapeutic agents are expensive, and their use must take into account economic...

Cite
Couchoud C, Fagnoni P, Aubin F, et al. Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. Cancer Immunol Immunother. 2020;69(10):1947-1958doi: 10.1007/s00262-020-02646-0.
Couchoud, C., Fagnoni, P., Aubin, F., Westeel, V., Maurina, T., Thiery-Vuillemin, A., Gerard, C., Kroemer, M., Borg, C., Limat, S., & Nerich, V. (2020). Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. Cancer immunology, immunotherapy : CII, 69(10), 1947-1958. https://doi.org/10.1007/s00262-020-02646-0
Couchoud, Charlotte, et al. "Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation." Cancer immunology, immunotherapy : CII vol. 69,10 (2020): 1947-1958. doi: https://doi.org/10.1007/s00262-020-02646-0
Couchoud C, Fagnoni P, Aubin F, Westeel V, Maurina T, Thiery-Vuillemin A, Gerard C, Kroemer M, Borg C, Limat S, Nerich V. Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. Cancer Immunol Immunother. 2020 Oct;69(10):1947-1958. doi: 10.1007/s00262-020-02646-0. Epub 2020 Jul 16. PMID: 32676716.
Copy Download .nbib Format: NLM
Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Guven DC, Sahin TK, Aksun MS, Taban H, Aktepe OH, Aksu NM, Akkaş M, Erman M, Kilickap S, Dizdar O, Aksoy S.
PMID: 32851486
Support Care Cancer. 2021 Apr;29(4):2029-2035. doi: 10.1007/s00520-020-05702-8. Epub 2020 Aug 26.

BACKGROUND: The emergency department (ED) is a crucial encounter point in cancer care. Yet, data on the causes of ED visits are limited in patients treated with immune checkpoint inhibitors (ICI). Therefore, we evaluated ED visits in patients treated...

Cite
Guven DC, Sahin TK, Aksun MS, et al. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Support Care Cancer. 2020;29(4):2029-2035doi: 10.1007/s00520-020-05702-8.
Guven, D. C., Sahin, T. K., Aksun, M. S., Taban, H., Aktepe, O. H., Aksu, N. M., Akkaş, M., Erman, M., Kilickap, S., Dizdar, O., & Aksoy, S. (2021). Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 29(4), 2029-2035. https://doi.org/10.1007/s00520-020-05702-8
Guven, Deniz Can, et al. "Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer vol. 29,4 (2021): 2029-2035. doi: https://doi.org/10.1007/s00520-020-05702-8
Guven DC, Sahin TK, Aksun MS, Taban H, Aktepe OH, Aksu NM, Akkaş M, Erman M, Kilickap S, Dizdar O, Aksoy S. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. Support Care Cancer. 2021 Apr;29(4):2029-2035. doi: 10.1007/s00520-020-05702-8. Epub 2020 Aug 26. PMID: 32851486.
Copy Download .nbib Format: NLM
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.

Current oncology reports

Mushti SL, Mulkey F, Tang S, Singh H, Lemery SJ, Goldberg KB, Sridhara R, Keegan P, Kluetz PG, Pazdur R, Theoret MR, Beaver JA.
PMID: 32851542
Curr Oncol Rep. 2020 Aug 27;22(11):116. doi: 10.1007/s11912-020-00974-z.

PURPOSE OF REVIEW: This review provides a comprehensive assessment of recent literature reports describing atypical response patterns observed with immune checkpoint inhibitors (ICIs), modifications to response evaluation criteria for ICIs, and treatment beyond progression in clinical trials.RECENT FINDINGS: Certain...

Cite
Mushti SL, Mulkey F, Tang S, et al. Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Curr Oncol Rep. 2020;22(11):116doi: 10.1007/s11912-020-00974-z.
Mushti, S. L., Mulkey, F., Tang, S., Singh, H., Lemery, S. J., Goldberg, K. B., Sridhara, R., Keegan, P., Kluetz, P. G., Pazdur, R., Theoret, M. R., & Beaver, J. A. (2020). Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Current oncology reports, 22(11), 116. https://doi.org/10.1007/s11912-020-00974-z
Mushti, Sirisha L, et al. "Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy." Current oncology reports vol. 22,11 (2020): 116. doi: https://doi.org/10.1007/s11912-020-00974-z
Mushti SL, Mulkey F, Tang S, Singh H, Lemery SJ, Goldberg KB, Sridhara R, Keegan P, Kluetz PG, Pazdur R, Theoret MR, Beaver JA. Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. Curr Oncol Rep. 2020 Aug 27;22(11):116. doi: 10.1007/s11912-020-00974-z. PMID: 32851542.
Copy Download .nbib Format: NLM
COVID-19 and immunomodulation treatment for women with reproductive failures.

Journal of reproductive immunology

Kwak-Kim J, Ota K, Sung N, Huang C, Alsubki L, Lee S, Han JW, Han A, Yang X, Saab W, Derbala Y, Wang WJ, He Q, Liao A, Takahashi T, Cavalcante MB, Barini R, Bao S, Fukui A, Lédée N, Coulam C.
PMID: 32603991
J Reprod Immunol. 2020 Sep;141:103168. doi: 10.1016/j.jri.2020.103168. Epub 2020 Jun 12.

COVID-19 pandemic is affecting various areas of health care, including human reproduction. Many women with reproductive failures, during the peri-implantation period and pregnancy, are on the immunotherapy using immune modulators and immunosuppressant due to underlying autoimmune diseases, cellular immune...

Cite
Kwak-Kim J, Ota K, Sung N, et al. COVID-19 and immunomodulation treatment for women with reproductive failures. J Reprod Immunol. 2020;141:103168doi: 10.1016/j.jri.2020.103168.
Kwak-Kim, J., Ota, K., Sung, N., Huang, C., Alsubki, L., Lee, S., Han, J. W., Han, A., Yang, X., Saab, W., Derbala, Y., Wang, W. J., He, Q., Liao, A., Takahashi, T., Cavalcante, M. B., Barini, R., Bao, S., Fukui, A., Lédée, N., & Coulam, C. (2020). COVID-19 and immunomodulation treatment for women with reproductive failures. Journal of reproductive immunology, 141103168. https://doi.org/10.1016/j.jri.2020.103168
Kwak-Kim, Joanne, et al. "COVID-19 and immunomodulation treatment for women with reproductive failures." Journal of reproductive immunology vol. 141 (2020): 103168. doi: https://doi.org/10.1016/j.jri.2020.103168
Kwak-Kim J, Ota K, Sung N, Huang C, Alsubki L, Lee S, Han JW, Han A, Yang X, Saab W, Derbala Y, Wang WJ, He Q, Liao A, Takahashi T, Cavalcante MB, Barini R, Bao S, Fukui A, Lédée N, Coulam C. COVID-19 and immunomodulation treatment for women with reproductive failures. J Reprod Immunol. 2020 Sep;141:103168. doi: 10.1016/j.jri.2020.103168. Epub 2020 Jun 12. PMID: 32603991; PMCID: PMC7291967.
Copy Download .nbib Format: NLM
Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report.

Journal for immunotherapy of cancer

Pinto C, Bergmann M, Briukhovetska D, Nuessler V, Sznol M, von Bergwelt-Baildon M, Kobold S.
PMID: 32114499
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000268.

Immunotherapy has moved to the forefront of cancer treatment, illustrated by the accelerating pace of novel therapy approvals. In this complex environment, scientists rely on cutting edge conferences to stay informed. The Immunotherapy of Cancer (ITOC) conference was established...

Cite
Pinto C, Bergmann M, Briukhovetska D, et al. Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report. J Immunother Cancer. 2020;8(1)doi: 10.1136/jitc-2019-000268.
Pinto, C., Bergmann, M., Briukhovetska, D., Nuessler, V., Sznol, M., von Bergwelt-Baildon, M., & Kobold, S. (2020). Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report. Journal for immunotherapy of cancer, 8(1), . https://doi.org/10.1136/jitc-2019-000268
Pinto, Catarina, et al. "Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report." Journal for immunotherapy of cancer vol. 8,1 (2020). doi: https://doi.org/10.1136/jitc-2019-000268
Pinto C, Bergmann M, Briukhovetska D, Nuessler V, Sznol M, von Bergwelt-Baildon M, Kobold S. Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report. J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000268. PMID: 32114499; PMCID: PMC7057436.
Copy Download .nbib Format: NLM
Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials.

Targeted oncology

Paliard X, Rixe O.
PMID: 31595386
Target Oncol. 2019 Dec;14(6):631-637. doi: 10.1007/s11523-019-00678-w.

The clinical development of cancer drugs is rapidly moving from empirical "one drug fits all" or development-by-tumor-type approaches towards more personalized treatment models. A deeper understanding of cancer and the immune system, novel technologies, and powerful analytics have fueled...

Cite
Paliard X, Rixe O. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials. Target Oncol. 2019;14(6):631-637doi: 10.1007/s11523-019-00678-w.
Paliard, X., & Rixe, O. (2019). Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials. Targeted oncology, 14(6), 631-637. https://doi.org/10.1007/s11523-019-00678-w
Paliard, Xavier, and Rixe, Olivier. "Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials." Targeted oncology vol. 14,6 (2019): 631-637. doi: https://doi.org/10.1007/s11523-019-00678-w
Paliard X, Rixe O. Precision Oncology for Cancer Immunotherapies in Early-Phase Clinical Trials. Target Oncol. 2019 Dec;14(6):631-637. doi: 10.1007/s11523-019-00678-w. PMID: 31595386; PMCID: PMC6875515.
Copy Download .nbib Format: NLM
Keeping Checkpoint Inhibitors in Check.

JAMA network open

Catenacci DVT, Hochster H, Klempner SJ.
PMID: 31050772
JAMA Netw Open. 2019 May 03;2(5):e192546. doi: 10.1001/jamanetworkopen.2019.2546.

No abstract available.

Cite
Catenacci DVT, Hochster H, Klempner SJ. Keeping Checkpoint Inhibitors in Check. JAMA Netw Open. 2019;2(5):e192546doi: 10.1001/jamanetworkopen.2019.2546.
Catenacci, D. V. T., Hochster, H., & Klempner, S. J. (2019). Keeping Checkpoint Inhibitors in Check. JAMA network open, 2(5), e192546. https://doi.org/10.1001/jamanetworkopen.2019.2546
Catenacci, Daniel V T, et al. "Keeping Checkpoint Inhibitors in Check." JAMA network open vol. 2,5 (2019): e192546. doi: https://doi.org/10.1001/jamanetworkopen.2019.2546
Catenacci DVT, Hochster H, Klempner SJ. Keeping Checkpoint Inhibitors in Check. JAMA Netw Open. 2019 May 03;2(5):e192546. doi: 10.1001/jamanetworkopen.2019.2546. PMID: 31050772.
Copy Download .nbib Format: NLM
Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents.

The Gulf journal of oncology

Abu-Shawer O, Bushnaq T, Abu-Shawer M.
PMID: 30956199
Gulf J Oncolog. 2019 Jan;1(29):76-82.

After several years of discouraging results, immunotherapy finally becomes a powerful, clinically valid and approved treatment for numerous types of cancer. Immunotherapy involves treatment approaches that work in various ways; some boost the body's immune system while others help...

Cite
Abu-Shawer O, Bushnaq T, Abu-Shawer M. Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents. Gulf J Oncolog. 2019;1(29):76-82
Abu-Shawer, O., Bushnaq, T., & Abu-Shawer, M. (2019). Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents. The Gulf journal of oncology, 1(29), 76-82.
Abu-Shawer, Osama, et al. "Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents." The Gulf journal of oncology vol. 1,29 (2019): 76-82.
Abu-Shawer O, Bushnaq T, Abu-Shawer M. Cancer Immunotherapy: An Updated Overview of Current Strategies and Therapeutic Agents. Gulf J Oncolog. 2019 Jan;1(29):76-82. PMID: 30956199.
Copy Download .nbib Format: NLM
Molecular and Translational Research on Colorectal Cancer.

International journal of molecular sciences

Passardi A, Scarpi E, Ulivi P.
PMID: 32526834
Int J Mol Sci. 2020 Jun 09;21(11). doi: 10.3390/ijms21114105.

Colorectal cancer (CRC) is the third most frequently diagnosed cancer in the world [...].

Cite
Passardi A, Scarpi E, Ulivi P. Molecular and Translational Research on Colorectal Cancer. Int J Mol Sci. 2020;21(11)doi: 10.3390/ijms21114105.
Passardi, A., Scarpi, E., & Ulivi, P. (2020). Molecular and Translational Research on Colorectal Cancer. International journal of molecular sciences, 21(11), . https://doi.org/10.3390/ijms21114105
Passardi, Alessandro, et al. "Molecular and Translational Research on Colorectal Cancer." International journal of molecular sciences vol. 21,11 (2020). doi: https://doi.org/10.3390/ijms21114105
Passardi A, Scarpi E, Ulivi P. Molecular and Translational Research on Colorectal Cancer. Int J Mol Sci. 2020 Jun 09;21(11). doi: 10.3390/ijms21114105. PMID: 32526834; PMCID: PMC7312519.
Copy Download .nbib Format: NLM
The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response.

Advances in experimental medicine and biology

Hipólito A, Mendes C, Serpa J.
PMID: 32130706
Adv Exp Med Biol. 2020;1219:311-333. doi: 10.1007/978-3-030-34025-4_16.

Lung cancer is the leading cause of cancer-related deaths worldwide in both men and women. Conventional chemotherapy has failed to provide long-term benefits for many patients and in the past decade, important advances were made to understand the underlying...

Cite
Hipólito A, Mendes C, Serpa J. The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response. Adv Exp Med Biol. 2020;1219:311-333doi: 10.1007/978-3-030-34025-4_16.
Hipólito, A., Mendes, C., & Serpa, J. (2020). The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response. Advances in experimental medicine and biology, 1219311-333. https://doi.org/10.1007/978-3-030-34025-4_16
Hipólito, Ana, et al. "The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response." Advances in experimental medicine and biology vol. 1219 (2020): 311-333. doi: https://doi.org/10.1007/978-3-030-34025-4_16
Hipólito A, Mendes C, Serpa J. The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response. Adv Exp Med Biol. 2020;1219:311-333. doi: 10.1007/978-3-030-34025-4_16. PMID: 32130706.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 94 entries